Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Transcode Therapeutics Inc
RNAZ
Healthcare
Biotechnology
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique...
, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:RNAZ)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 30, 2023 3:02pm
RNAZ..... P.O announcement
Withdrew the last one but....Here's a new one ; ) TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules 2023-11-30
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 14, 2023 4:30pm
New Press Release - TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2023, and recent business progress. ...
read article.
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 31, 2023 9:14am
RNAZ...Withdraws P.O....I f'king hope so !!!!
You've already done 2 P.O post RS yah mangy varmets .....Sheesh ....the last P.O was 16million shs at 51 cents Go chit in a river .... 10 : 1 they do a RS again ....maddapakkas
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 30, 2023 4:33pm
New Press Release - TransCode Therapeutics Withdraws Public Offering
BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it is withdrawing the underwritten public offering of its common stock. This...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 27, 2023 8:00am
New Press Release - Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced The Nasdaq Hearings Panel (“Panel”) granted the Company’s request to continue its...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 26, 2023 4:20pm
New Press Release - TransCode Therapeutics Announces Public Offering of Common Stock
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the commencement of an underwritten public offering of shares of its common stock...
read article.
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 26, 2023 10:59am
RNAZ.....green to red move? with volume....LoL
Since SH Admin deleted my last post....I will just have to re-phrase it and re-post it. It really amazes me how SH Admin polices all these posts of mine....all I do is tell it like it is....I know
...more
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 26, 2023 8:48am
RNAZ.... Exactly......Now what ??
These Pump deals are unreal The ST Guys are "hired assasins"
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 26, 2023 8:22am
RNAZ....ST Pumpers starting the Pump
here we go
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 26, 2023 8:18am
RNAZ....early a.m runner on News release (non-human test)
straight up to where the P.O was done at 51 cents Go ahead
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 24, 2023 8:00am
New Press Release - TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
Evidence of Drug Accumulation in Metastatic Lesions BOSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced preliminary results with its lead therapeutic...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 16, 2023 8:00am
New Press Release - TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA
Study showed a 70% Inhibition of Recurrent Tumor Growth BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported successful treatment of preclinical melanoma...
read article.
(69)
•••
Iseneschal
X
Comment by
Iseneschal
on Oct 09, 2023 2:01pm
RE:RE:RNAZ..This is the sad part about Pre-market & After Hours
This was my response to Tarbaby..... Hello Tarbaby...... I am only making assumptions from the date and time of your post....so all I can say is...... You bot the high trade on 09/20/23 Let me know
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 28, 2023 4:02pm
New Press Release - TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced public offering of an aggregate of 16,863...
read article.
(69)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 25, 2023 10:12pm
RNAZ.... Announces Pricing of $8 Million P.O
I'd say you've all been had....Again!!!! TransCode Therapeutics Announces Pricing of $8 Million Public Offering 2023-09-25 20:01 ET - News Release BOSTON
...more
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >